Arti Bhelekar

Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.

A. Mahajan, A. Bhattacharjee, K. Prabhash, 2020, The Lancet. Global health.

A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer

P. Chaturvedi, S. Kannan, A. Mahajan, 2019, Cancer.

Reverse swing‐M, phase 1 study of repurposing mebendazole in recurrent high‐grade glioma

A. Mahajan, A. Bhattacharjee, T. Gupta, 2020, Cancer medicine.

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV-negative oropharyngeal cancer

A. Mahajan, P. Pai, A. Bhattacharjee, 2019, Annals of Oncology.